BRG-01

N/A

Report date: 2024/12/25 20:00:50
First In Class

Base Information

Drug NameBRG-01
Drug Alias NameBRG01BRG-01
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionEpstein-Barr virus inhibitorsT lymphocyte replacementsImmunologic cytotoxicity
TargetsEpstein-Barr virus
Therapy Area/IndicationsHematologic NeoplasmsNasopharyngeal CarcinomaLymphoma, Large B-Cell, Diffuse +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesGuangzhou Baiji Biopharmaceutical Co LtdBiosyngen Pte Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGuangzhou Baiji Biopharmaceutical Co LtdBiosyngen Pte Ltd
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsNasopharyngeal CarcinomaLymphoma, Large B-Cell, Diffuse +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A